Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 24:46:101360.
doi: 10.1016/j.eclinm.2022.101360. eCollection 2022 Apr.

Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy

Vladimir A Gushchin  1 , Elena V Tsyganova  2 , Darya A Ogarkova  1 , Ruslan R Adgamov  1 , Dmitry V Shcheblyakov  1 , Nataliia V Glukhoedova  2 , Aleksandra S Zhilenkova  2 , Alexey G Kolotii  3 , Roman D Zaitsev  3 , Denis Y Logunov  1 , Alexander L Gintsburg  1 , Alexey I Mazus  2
Affiliations

Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy

Vladimir A Gushchin et al. EClinicalMedicine. .

Abstract

Background: HIV-infection is known to aggravate the course of many infectious diseases, including COVID-19. International guidance recommends vaccination of HIV+ individuals against SARS-CoV-2. There is a paucity of data on epidemiological efficacy assessment of COVID-19 vaccines among HIV+. This paper provides a preliminary assessment of Sputnik V vaccine effectiveness in HIV+ patients on antiretroviral therapy (ART).

Methods: We performed a retrospective cohort study to assess the effectiveness of the standard Sputnik V vaccination regimen in 24,423 HIV+ Moscow residents during spring - summer 2021, that included dominance of delta variant, with estimation of hospitalization and severe illness rates in vaccinated and unvaccinated patients. Data were extracted from the Moscow anti-COVID-19 vaccination and COVID-19 incidence Registries.

Findings: The data obtained indicate that Sputnik V epidemiological efficiency in the entire cohort of HIV+ on ART was 76·33%; in HIV+ with CD4+ ≥ 350 cells/µl, vaccine efficiency was 79·42%, avoiding hospitalization in 90·12% cases and protecting from the development of moderate or severe disease in 97·06%. For delta variant in this group the efficiency was 65·35%, avoiding the need for hospitalization in 75·77% cases and protecting from the development of moderate or severe disease in 93·05% of patients. There was a trend, although not statistically significant, of declining vaccine efficiency in immune-compromised individuals (CD4+ < 350 cells/µl).

Interpretation: The study suggested epidemiological efficiency of immunization with Sputnik V in HIV+ ART-treated patients for the original and delta SARS-CoV-2 variants.

Funding: Ministry of Health of Russia and Moscow Healthcare Department.

PubMed Disclaimer

Conflict of interest statement

ALG, DYL, DVS have patent pending for the Sputnik V immunobiological expression vector, pharmaceutical agent, in COVID-19 research. The patent owner is the “National Research Center for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation (Moscow, Russia). All other authors declare no competing interests.

References

    1. Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents: interim guidance for COVID-19 and persons with HIV. Updated February 2021. https://clinicalinfo.hiv.gov/en/guidelines/covid-19-and-persons-hiv-inte.... Accessed 6 March 2021
    1. Tebas P., Frank I., Lewis M., et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS. 2010;24:2187–2192. - PubMed
    1. Baden L.R., El Sahly H.M., Essink B., et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403–416. - PMC - PubMed
    1. Polack F.P., Thomas S.J., Kitchin N., et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603–2615. - PMC - PubMed
    1. Voysey M., Clemens S.A.C., Madhi S.A., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. - PMC - PubMed